Home » COVID-19
    • FILTER YOUR SEARCH
    Content Type:

    • COVID-19

    An Introduction to COVID-19

    On 11 March 2020, the World Health Organization declared COVID-19 a global pandemic. The impact on the medical community has been huge, not only on the front line of medical care but also for those navigating patient treatment during this unprecedented situation.

    The touchINFECTIOUS DISEASES expert faculty have been sharing their experiences and advice during this challenging time through video interviews and short articles.

    COVID-19 Content

    COVID-19
    Rifaat Safadi, EASL ILC 2021: Impact of Liver Disease on SARS-CoV-2 Vaccine Response

    It was a pleasure to speak with Prof. Rifaat Safadi (Hadassah University Hospital, Ein Kerem, Jerusalem) about the impact of advanced chronic liver disease on the efficacy of the Pfizer and Moderna mRNA SARS-CoV-2 vaccines. His abstract entitled ‘Elderly with advanced liver fibrosis had lower response to Pfizer’s SARS-CoV-2 vaccine response’ was presented at EASL […]

    Viral Infections, COVID-19
    Timothy Hinks, ECCMID 2021: ATOMIC2 Study Results

    touchINFECTIOUSDISEASES were pleased to meet with Timothy Hinks (Nuffield Department of Medicine, University of Oxford, Oxford, UK) to discuss the results of the ATOMIC2 study results, investigating azithromycin in the treatment of COVID-19. The abstract entitled: ‘A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19: the ATOMIC2 trial’ was presented at the […]

    Viral Infections, COVID-19
    Beatriz Mateos, EASL ILC 2021: Tenofovir in Hepatitis B Patients with COVID-19

    It was lovely to speak with Dr Beatriz Mateos (Universidad de Alcalá, Madrid, Spain) about the findings from her research into the impact of tenofovir on the severity of COVID-19 infection in those with chronic hepatitis B. Her presentation entitled ‘Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients’ was given at […]

    Viral Infections, COVID-19
    Alba Grifoni, HIVR4P 2021: T Cell Responses of SARS-CoV-2 Epitopes

    We were delighted to have the opportunity to speak with Dr Alba Grifoni ( La Jolla Institute for Immunology, La Jolla, CA, USA) to discuss T Cell responses of SARS-CoV-2 epitopes in COVID-19 cases. Her abstract entitled: ‘B & T cell interactions: New studies on COVID-19’ (SY08.05) was presented at the HIVR4P Virtual Conference 2021, […]

    Viral Infections, COVID-19
    Carlos Chaccour, ISNTD d3 2021: Ivermectin for COVID-19

    It was a delight to be able to speak with Dr Carlos Chaccour (University of Barcelona, Barcelona, Spain) about the controversy currently surrounding the use of ivermectin for the treatment of COVID-19. His presentation entitled Ivermectin and COVID: what’s going on?  was presented at the ISNTD d3 2021 Virtual Congress, 24-25 February. Questions: Could you […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72